Mindset Pharma Inc. and Emerging
Markets Consulting, LLC.
ORLANDO, FL -- February 16, 2022 -- InvestorsHub NewsWire -- via
Emerging Markets -- Important news from Mindset Pharma
Inc. (Mindset) (CSE:
MSET) (FSE: 9DF) (OTCQB:
MSSTF), a drug discovery and development company
focused on creating next-generation psychedelic medicines to treat
neurological and psychiatric disorders appears to have reached a
significant milestone for the Company and its shareholders.
Frankly put, news that
the Company's psychedelic medicines could be useful to a
broader market is important from a simple financial standpoint. It
doesn't take an economist to note that a broader market could
portend potential revenue.
But it's important to remember that this isn't a picks and
shovels deal. Not selling any hubcaps either.
This is a Company at the forefront of the psychedelic
revolution, a Company which is endeavoring to create optimized and
patentable next-generation psychedelic medicines to treat
neurological and psychiatric disorders with unmet medical
needs.
In the release, James Lanthier, CEO of Mindset was clear that
"…it has synthesized additional promising candidates from its
Family 3 of next-generation drug candidates, and will initiate
Proof of Concept preclinical studies to further measure the
viability of these compounds as daily pro-cognitive take-home
medication."
Further in the release Mindset speaks directly to the expanding
market opportunity which as the paragraph concludes, touches on two
potentially large markets. It is important to note with emphasis
that these remarks regard a Company still very much in the Research
and Development phase and that no efficacy or outcome is
certain.
Now back to CEO Lanthier's remarks.
"If we can demonstrate pro-cognitive benefits at a range of
sub-hallucinogenic doses, our compounds have the potential to
dramatically broaden the addressable neurology and mental health
market we are pursuing while avoiding the hallucinogenic liability
associated with traditional approaches. Providing pro-cognitive
solutions that do not elicit a psychedelic effect will suit
vulnerable patient populations such as juvenile ADHD, Alzheimer's
disease, and a range of others."
For us, the science being developed at Mindset is emboldened by
their previously reported news that the Company had entered in to a
first-of-its-kind co-development agreement with the McQuade Center
of Strategic Research and Development, a member of the Otsuka
Pharmaceuticals family of companies, which fully funds and advances
the development of Mindset's Family 2 & Family 4. Family 3
compounds are potential opportunities for Mindset to partner with
other groups to progress its most promising candidates from this
family to the clinic.
Here's a horses' mouth account of the pact:
https://youtu.be/4gg0QKfwmrI
If you're of the short attention span persuasion or only have a
second, cruise to the 1:13 minute mark of that video and listen to
that sentence. See what he says about their aspirations to design a
drug with some of the same benefits of psychedelic
drugs without the trips.
Here's a hint: it may create a much larger market.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated
by Emerging Markets Consulting (EMC), a syndicate of investor
relations consultants representing years of experience. Our network
consists of stockbrokers, investment bankers, fund managers, and
institutions that actively seek opportunities in the micro and
small-cap equity markets.
For more informative reports such as this, please sign up
at https://emergingmarketsconsulting.com/
Must Read OTC Markets/SEC policy on stock promotion and
investor protection
Section 17(b) of the Securities Act of 1933 requires that any
person that uses the mails to publish, give publicity to, or
circulate any publication or communication that describes a
security in return for consideration received or to be received
directly or indirectly from an issuer, underwriter, or dealer, must
fully disclose the type of consideration (i.e. cash, free trading
stock, restricted stock, stock options, stock warrants) and the
specific amount of the consideration. In connection therewith, EMC
has received the following compensation and/or has an agreement to
receive in the future certain compensation, as described below.
EMC has been paid $250,000 by Mindset Pharma, Inc. for various
marketing services including this report. EMC does not
independently verify any of the content linked-to from this
editorial. https://emergingmarketsconsulting.com/disclaimer/
Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave STE 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/
SOURCE: Emerging Markets
Mindset Pharma (CSE:MSET)
過去 株価チャート
から 11 2024 まで 12 2024
Mindset Pharma (CSE:MSET)
過去 株価チャート
から 12 2023 まで 12 2024
